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tient age, sex, number of pre-index antidiabetic medications (1.90.9), pre-index
HbA1c (8.21.5%), or Charlson Comorbidity Index (0.450.78, all p.05). Mean (SD)
ADDwas 16.7mcg (9.22; label range 10-20mcg) for exenatide patients and 1.43mg
(0.69, label range 0.6-1.8 mg) for liraglutide patients. Among patients with post-
index HbA1c tests, mean values did not differ at the first (7.9), second (7.8), or third
(7.8, all p.05) tests. Exenatide patients were more likely than liraglutide patients
to continue pre-index anti-diabeticmedications (67.1% vs. 60.3%, p.027) or to start
concomitant anti-diabeticmedications at index (32.2% vs. 25.0%, p.013); however,
exenatide patients were less likely to augment treatment post-index (15.8% vs.
22.5%, p.027). Post-index, 9.3% exenatide and 10% liraglutide patients discontin-
ued GLP-1 therapy (p.05). CONCLUSIONS: Results suggest that some differences
exist between German patients initiating exenatide or liraglutide, with respect to
prescribing physician specialty, pre-and post-index treatment patterns, and ADD.
Both GLP-1s show comparable post-index HbA1c.
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OBJECTIVES: This study describes baseline characteristics and prior antidiabetic
therapy of patients in an electronic medical record (EMR) prescribed liraglutide, a
once-daily GLP-1 agonist, relative to non-liraglutide patients. METHODS: Adults
(18 years) with T2DM, a new prescription for liraglutide from 3/10/2010 to 7/16/
2010 (index date), and EMR activity395 days pre-index to1 day post-index were
identified. Demographics, comorbidities, and pre-index antidiabetic prescriptions
orders were compared to adults with T2DM, 1 non-liraglutide antidiabetic order
from1/1/2010 to 7/16/2010 (index date), and EMR activity395 days pre-index to1
day post-index. Bootstrapping was used to provide robust mean (95% CI) estimates
for comparison patients due to sample size (n247,922). RESULTS:Of 1,162 liraglu-
tide patients, 58.8% were female and mean (95% CI) age was 55.5 (54.9, 56.2) years
vs. 53.0% female and 60.9 (60.1, 61.6) years for comparison patients. For liraglutide
vs. comparison patients, mean baseline HbA1c was 8.1% (8.0, 8.2) vs. 7.6% (7.5, 7.8),
BMI was 38.3 kg/m2 (37.8, 38.8) vs. 34.1 kg/m2 (33.6, 34.6), body weight was 109.5 kg
(108.0, 111.0) vs. 96.7 kg (95.1, 98.3). Comorbidities in liraglutide vs. comparison
patients included dyslipidemia (87.1% vs. 79.2%), hypertension (73.6% vs. 73.8%),
and cardiovascular disease (18.2% vs. 22.4%). Of liraglutide patients, 5.6% were
antidiabetic drug naive pre-index vs. 42.0% of comparison patients. Themost com-
mon antidiabetics prescribed any time the year pre-index were metformin and
sulfonylureas, respectively, for liraglutide (64.5%, 37.5%) and comparison (28.7%,
19.6%) patients, followed by insulin (33.8% liraglutide vs. 19.6% comparison). Pre-
index orders formultiple antidiabetics occurred in 75.6% of liraglutide and 22.5% of
comparison patients (p0.01 for all comparisons except hypertension p.05).
CONCLUSIONS: Early data suggest that liraglutide is being utilized in very obese
patients who failed to achieve HbA1c goal on other antidiabetics. Longitudinal
research is warranted to assess liraglutide outcomes and changes in antidiabetics
post-liraglutide.
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OBJECTIVES: To examine characteristics of physicians who are early adopters of
new expensive drugsMETHODS: Retrospective analysis of pharmacy claims from
2006-2010 for 3 expensive diabetes drugs (exenatide, saxagliptin, and sitagliptin)
identified by medical directors and pharmacists at large health plan in Hawaii. We
examined how physician specialty and urban setting affected likelihood of being
an early prescriber. We calculated total paid costs and days supply by quarter for
each physician. We also examined whether same physicians tended to be early
adopters of all drugs. RESULTS: Characteristics of early adopters differed by med-
ication. For saxagliptin, during first 2 quarters, 53% of prescriptions were made by
internists, 30%by general/family practitioners, 17%by other specialists and1%by
endocrinologists. This distribution stayed fairly stable over time. In contrast, for
exenatide, in first 2 quarters usage was highest for endocrinologists (28%), Medic-
aid providers (29%) or other specialists (25%). By the end of 2010, however, most
exenatide prescriptions were being made by internists or general/family practitio-
ners. The trends for sitagliptin were similar to that of exenatide with endocrinol-
ogists (32%), Medicaid (34%) and other specialists (30%) being early adopters with a
shift towardmore prescriptions by primary care physicians. Early adopters tended
to be in urban areas. 75% of physicians were early prescribers of one drugs, 25%
were early prescribers of two drugs, and none were early prescribers of all three
medications. CONCLUSIONS: Research of this nature may enable us to target in-
tervention programs to promote cost-effective prescribing patterns.
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OBJECTIVES: The purpose of this project is to investigate the interaction effects of
diabetes complications on Medicare expenditures, length of hospitalization, claim
frequency and mortality of diabetes inpatients in the Medicare population.
METHODS: The analysis is based on inpatient claims data with 244,299 records for
the year 2004, from CMS (the Centers for Medicare and Medicare Services) chronic
condition data warehouse. In this study, the RXMATCH function, summary statis-
tics and 0-1 indicator functions are used to generate the predictor variables, heart
disease, kidney disease, neurologic disorder, ocular disease and hypertension. The
generalized linearmodel with a gammadistribution is employed for the analysis of
interaction effects of complications on Medicare payments and length of stay
(LOS). The Poisson regression model is applied to analyze the effects on the fre-
quency of claims. The logistic regression model is utilized to study the effects on
mortality. RESULTS: Results demonstrate that several two-way interactions such
as heart disease and eye disease, heart disease and hypertension are significant to
costs and LOS. The effects between kidney disease and cardiovascular disease are
significant in the Poisson regression model. The interaction effect between renal
disease and cardiovascular disease is significant tomortality.CONCLUSIONS:After
the study, we can conclude that for inpatients with other diabetes complications,
there are differences in health costs and health outcomes between the inpatients
who have cardiovascular disease and those who do not have. There also exist big
differences in outcomes between the patients who have renal disease and those
who do not have.
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OBJECTIVES: An important challenge addressing researchers studying adherence
among insulin-requiring patients with diabetes is the discrepancy between the
point-of-sale (POS) entered days supply and the actual time of medication posses-
sion. Significant deviation between these two can result in misleading medication
passion ratio (MPR) estimates, especially in cases where the quantity dispensed is
known to differ significantly, as is the casewith insulin detemir delivered in a 15mL
FlexPen® (IDetFP) pack versus NPH insulin delivered in a 10mL vial. This research
expands upon an approach used by Klienman et al., and suggests an alternative
measure of medication possession for insulins. METHODS: Data were gathered
from a large US national payer retrospective claims database, and included only
patients 18 years of age with type 2 diabetes that had 2 retail pharmacy fills of
IDetFP or NPH vial in a 12-month observation period. Patients with claims for any
other insulin, other than the index insulin during the 12-month observation period,
were excluded. Median empirically-derived days supply (EDDS) estimates, based
on median time-to-next-refill intervals, and POS entered days supplies were com-
pared within and between cohorts. RESULTS: Median POS days supply estimates
were identical for both the IDetFP and NPH cohorts, 30.00 days for both; however,
median EDDS were significantly different between IDet and NPH cohorts, 45.00 vs.
36.00, respectively (p0.001). In addition, within-group comparisons of POS days
supply and EDDS in both cohorts revealed significant differences (p0.001 for both
tests). CONCLUSIONS: Drawing meaningful conclusions about adherence with in-
sulins using pharmacy claims remains a significant challenge. Our analysis dem-
onstrates that POS days supply entries, commonly used for adherence analysis,
may deviate substantially and significantly from EDDS estimates. This study ex-
plores a novel, alternative, and empirically-based approach to determining medi-
cation possession. Research to further refine this and suggest other alternative
methods should be encouraged.
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OBJECTIVES: To perform a beta-verification of a novel diabetesmodeling and anal-
ysis framework (DMAF) designed to accommodate growing demand for analysis on
ever-shifting special subpopulations, new interventions, and updated care algo-
rithms. A Monte Carlo microsimulation model assuming standard oral and subse-
quent insulin therapy generated mean outcomes as defined by recently published
trials: 1) ACCORD-BPLI; 2) ACCORD-GLI; 3) ASPEN; and 4) ADVANCE. METHODS:
Diabetes is increasing in prevalence, and its 20-year history of diabetes care has
witnessed a shift from treating complications to prevention based on evidence
from: The United Kingdom Prospective Diabetes Study, Diabetes Control and Com-
plications Trials, and the Wisconsin Epidemiological Study of Diabetic Retinopa-
thy. All have confirmed that tight control of hemoglobin A1c reduced the incidence
of complications. Recent trials of diabetics have evaluated targeted interventions
for clinical factors and impact on complication rates. Evidence from these trials
suggests that aggressive A1c targets may not be suitable for all patients. The evo-
lution of decision models for diabetes has paralleled that of care. Increased prev-
alence has placed pressure on health care costs and expectations that new inter-
ventions impart significant benefits. New evidence has in turn motivated
development of decisionmodels that evaluate new interventions, treatments, and
care algorithms. RESULTS: The DMAFwas reasonably consistent withwell-defined
composite endpoints for ASPEN (15.0% vs. 17.1%); ADVANCE: Secondary (10.5% vs.
9.6%), fatal MI (5.7% vs. 5.5%), all coronary events (11.9% vs. 10.3%); and ACCORD-
BPLI non-fatal MI (1.4% vs. 1.3%). DMAF showed results within orders ofmagnitude
for endpoints such as ASPEN angina (2.6% vs. 3.1%); ACCORD-BPLI: heart failure
(0.5% vs. 0.8%), major coronary event (3.1% vs. 2.4%), primary outcome (3.6% vs.
2.1%); ACC ORD-GLI non-fatal MI (6.5% vs. 4.6%). CONCLUSIONS: Trial outcomes
defined as “new or worsening” were not well-matched by DMAF due possibly to
uncertainty in definitions and suitability for modeling.
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